BridgeBio Oncology Therapeutics

👥 24 employees💰 Last funded May 2024
Biotechnology Research🌐 bridgebiooncology.com
Website LinkedIn
BridgeBio Oncology Therapeutics is a clinical-stage biopharmaceutical company advancing a next generation pipeline of novel small molecule therapeutics targeting RAS and PI3K malignancies. Initially formed as a subsidiary of BridgeBio, BridgeBio Oncology Therapeutics completed a $200M private financing with external investors in 2024 with the goal of improving outcomes for patients with cancers driven by the two most prevalent oncogenes in human tumors.
1
Total investors
0
Early stage
0
Mid stage
0
Late stage
—
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in BridgeBio Oncology Therapeutics?
BridgeBio Oncology Therapeutics has 1 investors on record on gritt.io.
When did BridgeBio Oncology Therapeutics last raise funding?
The most recent investment in BridgeBio Oncology Therapeutics recorded on gritt.io was in May 2024.
What industry is BridgeBio Oncology Therapeutics in?
BridgeBio Oncology Therapeutics operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.